Previous 10 | Next 10 |
home / stock / alpmf / alpmf news
2023-09-19 09:29:45 ET More on Astellas, Apellis, etc. Sticking With Apellis: Navigating Syfovre's Safety Measures In A Volatile Market Apellis: Exercise Caution In Response To Safety Signal (Rating Downgrade) Wells Fargo ups Apellis to overweight, stock climbs ...
2023-09-14 04:51:56 ET Astellas Pharma ( OTCPK:ALPMY ) intends to build a new facility, at an approximate cost of €330M in Tralee, Co. Kerry. Ireland. This investment will expand capacity and capabilities for aseptic drug products, reinforce stable production...
2023-09-07 15:39:56 ET Japanese drugmaker Astellas ( OTCPK:ALPMF ) has withdrawn a federal lawsuit that challenged the US government’s right to negotiate drug prices for its Medicare program, but maintained the newly instituted policy was unconstitutional. Astellas was one of...
2023-08-23 08:12:30 ET More on Pfizer Pfizer Stock: The Right Time To Buy Now (Technical Analysis) Pfizer: Doubling Down Buying Opportunity Is Here Pfizer's Unexpected Strength: Bullish Case Emerges Amid New Covid-19 Wave Pfizer Inc. ( PFE ) Q2 2023 Ear...
2023-08-16 12:41:31 ET Summary Astellas has closed its Iveric bio, Inc. deal in July and reported JPY 375Bn in quarterly sales in Q1. The company's earnings power and asset factors are bullish, but valuation factors are keeping me neutral. From this, I am closely watching the ...
2023-08-14 07:55:03 ET Summary George Soros's 13F portfolio value decreased slightly from $6.49B to $6.41B, with 172 positions. New stakes include PDC Energy, IVERIC bio, ARK Innovation ETF Calls, Alibaba Group Holding, Five9 Puts, RenaissanceRE Holdings, and MicroStrategy Puts. ...
2023-08-14 07:00:00 ET Summary Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market. The direction of the 10-year bond yield has become a key predictor of biotech industry pe...
2023-08-07 13:54:42 ET More on Apellis Apellis: Exercise Caution In Response To Safety Signal (Rating Downgrade) Apellis Pharmaceuticals: Biotech's Rising Star In C3 Inhibition Space Apellis extends selloff as JPMorgan becomes latest to downgrade Apellis off ...
2023-08-07 11:25:39 ET More on Poseida Poseida Therapeutics: Pioneering Cell And Gene Therapies Spark Excitement And Caution Poseida gains on FDA nod to start trials for CAR-T therapy Poseida stock falls ~8% postmarket after founder, executive chairman to step down ...
2023-08-06 22:42:08 ET Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Conference Call August 01, 2023, 04:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Naoki Okamura - Representative Director, President and CEO Yoshitsugu S...
News, Short Squeeze, Breakout and More Instantly...
Astellas Pharma Inc Company Name:
ALPMF Stock Symbol:
OTCMKTS Market:
Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...
One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca 's (NYSE: AZN) lung cancer drug Tagrisso. A few months ago, the pharmaceutical giant argued that the drug should receive...
This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, ...